Analyst Ryan MacDonald of Needham maintained a Buy rating on DocGo, retaining the price target of $3.00.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Ryan MacDonald has given his Buy rating due to a combination of factors surrounding DocGo’s recent acquisition of SteadyMD. The acquisition is expected to significantly enhance DocGo’s clinical capacity and geographic reach, particularly benefiting its growing payer segment. Additionally, the integration of SteadyMD’s telehealth platform is anticipated to improve gross margins by up to 10%, while the combined technology platforms are set to boost patient engagement, scheduling, and operational efficiency.
MacDonald views this acquisition as a capital-efficient strategy to expand DocGo’s capacity and enhance its structural profitability. The anticipated synergies, expected to be realized by the first half of 2026, contribute to the positive outlook on DocGo’s transition story, which MacDonald believes is undervalued by the market. As a result, he maintains a bullish stance on the stock, recommending it as a Buy.
MacDonald covers the Technology sector, focusing on stocks such as Duolingo, Liveperson, and Yext. According to TipRanks, MacDonald has an average return of 3.5% and a 45.09% success rate on recommended stocks.